Table 1.
Pharmacological modulation of pain-related behavior in MIA model of osteoarthritis.
| Compound | Dose (mg/kg) | Observed changes in pain-related behavior | References | |
|---|---|---|---|---|
| Early phase | Late phase | |||
| Diclofenac | 30 | M.H. | – | (Fernihough et al., 2004) |
| Morphine | 6 | M.A., M.H. | M.H., M.A., W.B. | (Combe et al., 2004; Fernihough et al., 2004; Pomonis et al., 2005) |
| Gabapentin | 6 | – | M.A., W.B | (Fernihough et al., 2004; Ivanavicius et al., 2007) |
| Paracetamol | 1 | M.H. | W.B. | (Fernihough et al., 2004) (Bove et al., 2003) |
| Naproxen | 10 | – | W.B. | (Bove et al., 2003) |
| Rofecoxib | 10 | – | W.B. | (Bove et al., 2003) |
| Tramadol | 3 | – | M.A., W.B. | (Combe et al., 2004) |
| CGRP8-37 | 5nmol/5 µl/mouse | – | M.A. | (Ogbonna et al., 2013) |
| Indomethacin | 3 | – | W.B. | (Pomonis et al., 2005) |
| Celecoxib | 3 | – | W.B. | (Pomonis et al., 2005) |
| A-796260* | 35 | – | M.E. | (Yao et al., 2008) |
| URB597** | 5 | – | W.B. | (Schuelert et al., 2011) |
| PF-04457845 | 0.3 | – | M.H. | (Ahn et al., 2011) |
| Amitriptyline | 3 | – | W.B. | (Ivanavicius et al., 2007) |
| A-889425*** | 30 | – | M.E. | (Chu et al., 2011) |
| Anti-NGF antibody | 5 | M.A. | – | (Sousa-Valente et al., 2018) |
| PD98059+ | 10 µl | – | M.E. | (Lee et al., 2011) |
| BIBN4096BS++ | 3 | W.B. | – | (Hirsch et al., 2013) |
| Minocycline+++ | 30 | – | M.A | (Sagar et al., 2011) |
M.A, referred mechanical hyperalgesia; measured with von Frey apparatus; M.H, mechanical hyperalgesia, measured with Randall–Salito; W.B, weight bearing, measured with incapacitance tester; M.E, movement-evoked pain, grip force test.
*CB2 agonist.
**FAAH inhibitor.
***TRPV1 antagonist.
+MAPK1 inhibitor.
++CGRP antagonist.
+++glial cell inhibitor.